wogonin and Cardiomegaly

wogonin has been researched along with Cardiomegaly* in 1 studies

Other Studies

1 other study(ies) available for wogonin and Cardiomegaly

ArticleYear
Wogonin Inhibits Cardiac Hypertrophy by Activating Nrf-2-Mediated Antioxidant Responses.
    Cardiovascular therapeutics, 2021, Volume: 2021

    Cardiac hypertrophy is one of the initial disorders of the cardiovascular system and can induce heart failure. Oxidative stress is an important pathophysiological mechanism of cardiac hypertrophy. Wogonin (Wog), an important flavonoid derived from the root of. Our results showed that Wog significantly ameliorated AngII-induced cardiomyocyte hypertrophy by inhibiting oxidative stress in H9C2 cells and NRCMs. In addition, Wog treatment prevented oxidative stress and improved cardiac hypertrophy in mice that underwent TAC. Using gene-specific siRNA for. Our results provide further evidence for the potential use of Wog as an antioxidative agent for treatment of cardiac hypertrophy, and Nrf-2 might serve as a therapeutic target in the treatment of cardiac hypertrophy.

    Topics: Animals; Antioxidants; Cardiomegaly; Flavanones; Mice; Mice, Inbred C57BL; Myocardium; Myocytes, Cardiac; Rats

2021